IBM announced a self-hosted deployment option for its AI software development platform, IBM Bob, enabling organizations to run AI-powered software development and modernization within their own controlled environments such as on-premises, private clouds, and air-gapped systems. This addresses security, compliance, and data sovereignty concerns critical for enterprises managing sensitive code and regulated data. The move supports hybrid and edge AI infrastructure trends, allowing companies to keep data in place while leveraging AI, thus enhancing control over AI governance and operational security. IBM Bob's flexibility aims to accelerate AI adoption in regulated industries by integrating AI directly into existing infrastructure without moving data externally.
IBM's new self-hosted deployment for IBM Bob offers enterprises enhanced AI sovereignty and governance. For readers following technology stocks, here is Pluang's market snapshot as of Oct 01, 2026 10:51 WIB: out of 150 priced Technology-sector US stocks, 108 rose and 41 fell. Notable movers include Applovin Corporation (APP) at USD 292.08 with a 1-day change of -4.44%, Mongodb Inc (MDB) at USD 351.91 with +4.37%, and Mondaycom Ltd (MNDY) at USD 79.24 with +4.19%. Typical hold times range from 15 to 45 days, with varying buy/sell order activity.
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
The VanEck Semiconductor ETF (SMH) dropped nearly 10% due to a rotation of capital from AI and tech stocks into sectors like Financials and Energy amid worsening liquidity and macroeconomic challenges. The portfolio manager reduced cash holdings from...
Telix Pharmaceuticals and Ekalia have teamed up to establish U.S.-based production of astatine-211, a rare alpha-emitting isotope used in targeted alpha therapy for cancer. This collaboration combines IBA's cyclotron technology, Framatome's nuclear e...
Ekalia, a joint venture between IBA and Framatome, has partnered with Telix Pharmaceuticals to accelerate the production of Astatine-211, a promising alpha-emitting radioisotope used in targeted cancer therapies, in the United States. The collaborati...
